-
1
المؤلفون: Jones H, Campbell Rd, Wendy Thomson, Albertella Mr, Mark G. Olavesen
المصدر: Genomics. 36(2)
مصطلحات موضوعية: Genetics, Male, Base Sequence, Molecular Sequence Data, Locus (genetics), HL-60 Cells, Orchitis, Biology, Protein Serine-Threonine Kinases, Molecular biology, Homology (biology), Major Histocompatibility Complex, genomic DNA, Intergenic region, Exon trapping, Gene mapping, Complementary DNA, Tumor Cells, Cultured, Humans, Disease Susceptibility, Casein Kinase II, Gene, HeLa Cells
-
2
المؤلفون: Albertella Mr, Wendy Thomson, Jones H, Neville Mj, Campbell Rd, Olavesen Mg
المصدر: DNA sequence : the journal of DNA sequencing and mapping. 7(1)
مصطلحات موضوعية: DNA, Complementary, Sequence analysis, Restriction Mapping, Biology, Protein Serine-Threonine Kinases, Major histocompatibility complex, Biochemistry, Major Histocompatibility Complex, Endocrinology, Restriction map, Casein kinase 2, alpha 1, Genetics, Humans, Genomic library, HSP70 Heat-Shock Proteins, Casein Kinase II, Molecular Biology, Gene, Gene Library, Protein-Serine-Threonine Kinases, RNA Nucleotidyltransferases, Sequence Analysis, DNA, Blotting, Northern, Molecular biology, Blotting, Southern, biology.protein, Casein kinase 2, RNA Helicases
-
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
8دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
9دورية أكاديمية
المؤلفون: Guirguis AA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia., Ofir-Rosenfeld Y; Storm Therapeutics Ltd, Cambridge, United Kingdom., Knezevic K; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Blackaby W; Storm Therapeutics Ltd, Cambridge, United Kingdom., Hardick D; Storm Therapeutics Ltd, Cambridge, United Kingdom., Chan YC; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Motazedian A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Gillespie A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Vassiliadis D; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Lam EYN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Tran K; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Andrews B; Storm Therapeutics Ltd, Cambridge, United Kingdom., Harbour ME; Storm Therapeutics Ltd, Cambridge, United Kingdom., Vasiliauskaite L; Storm Therapeutics Ltd, Cambridge, United Kingdom., Saunders CJ; Storm Therapeutics Ltd, Cambridge, United Kingdom., Tsagkogeorga G; Storm Therapeutics Ltd, Cambridge, United Kingdom.; Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom., Azevedo A; Storm Therapeutics Ltd, Cambridge, United Kingdom., Obacz J; Storm Therapeutics Ltd, Cambridge, United Kingdom., Pilka ES; Evotec (UK) Ltd, Abingdon, United Kingdom., Carkill M; Charles River Laboratories, Portishead, United -Kingdom., MacPherson L; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Wainwright EN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Liddicoat B; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Blyth BJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Albertella MR; Storm Therapeutics Ltd, Cambridge, United Kingdom., Rausch O; Storm Therapeutics Ltd, Cambridge, United Kingdom., Dawson MA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, -Victoria, Australia.
المصدر: Cancer discovery [Cancer Discov] 2023 Oct 05; Vol. 13 (10), pp. 2228-2247.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
مواضيع طبية MeSH: Interferons*/genetics , Methyltransferases*/genetics , Methyltransferases*/metabolism, Animals ; Mice ; RNA, Double-Stranded
-
10دورية أكاديمية
المؤلفون: Dellavedova G; Cancer Metastasis Therapeutics, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Decio A; Cancer Metastasis Therapeutics, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Formenti L; Cancer Metastasis Therapeutics, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Albertella MR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wilson J; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Staniszewska AD; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Leo E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Giavazzi R; Cancer Metastasis Therapeutics, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Ghilardi C; Cancer Metastasis Therapeutics, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Bani MR; Cancer Metastasis Therapeutics, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
المصدر: Cancer research communications [Cancer Res Commun] 2023 Mar 27; Vol. 3 (3), pp. 489-500. Date of Electronic Publication: 2023 Mar 27 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun
مواضيع طبية MeSH: Ovarian Neoplasms*/drug therapy , Adenocarcinoma*/drug therapy, Female ; Humans ; Animals ; Mice ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Carboplatin/therapeutic use ; Heterografts ; Platinum/therapeutic use ; BRCA2 Protein ; Carcinoma, Ovarian Epithelial/drug therapy ; Disease Models, Animal ; Poly (ADP-Ribose) Polymerase-1/therapeutic use
PDF full text from Publisher 
Full Text Finder